Palmitoylcarnitine (10 mg/kg, s.c., once daily for 28 days) induces insulin resistance and hyperinsulinemia, leading to glucose metabolism impairment in CD-1 mice[3].
Palmitoylcarnitine (50 mg/kg, s.c., single dose) reduces insulin sensitivity and induces glucose intolerance and metabolic dysfunction in CD-1 mice[3].
Palmitoylcarnitine (50 mg/kg, i.p., single dose) increases muscle long-chain acylcarnitine content and induces insulin resistance in CD-1 mice, characterized by hyperglycemia and reduced muscle glucose uptake[3].
| Animal Model: | Palmitoylcarnitine (HY-126357)-induced insulin resistance CD-1 mouse model[3] |
| Dosage: | 50 mg/kg (s.c. or i.p., single dose) or 10 mg/kg (s.c., long-term administration) |
| Administration: | Intraperitoneal injection (i.p.), single dose;
Continuously released for 24 hours via a subcutaneous osmotic minipump (s.c.)., single dose
Subcutaneous osmotic minipump (s.c.), once daily for 28 days. |
| Result: | Increased muscle long-chain acylcarnitine content, elevated blood glucose levels in both fasted and fed states, and decreased muscle glucose uptake (i.p.).
Induced glucose intolerance, delayed energy metabolism shift, and reduced insulin sensitivity (s.c., single dose).
induced insulin resistance and hyperinsulinemia, blocked insulin-mediated blood glucose reduction, increased blood lactate levels, and impaired glucose metabolism (s.c., long-term administration).
|
